debate | dr t p sahoo | is osimertinib the best option for first line treatment of egfr mutant
Published 1 year ago • 36 plays • Length 15:22Download video MP4
Download video MP3
Similar videos
-
7:48
dr kiran | osimertinib resistance mechanisms
-
5:48
dr vamshi krishna | osimertinib vs dacomitinib
-
7:18
dr sunil chopade | a randomised phase ii study of osimertinib and bevacizumab versus bevacizumab
-
2:06
2020 ttf egfr qa panel updates combo treatment of osimertinib (tagrisso) & ramucirumab (cyramza)
-
1:44
osimertinib and chemotherapy in egfr lung cancer with tp53 and rb1 alterations
-
11:54
debate: targeted therapy for ras/braf wt left sided colon cancers - bevacizumab or egfr antibodies
-
18:44
lung cancer: egfr l858r- exon21 exon 18 - e709k positive. pet scan after 22months w/ tagrisso
-
17:42
oligoprogressive non-small cell lung cancer | 2024 living with egfr-mutant lung cancer patient forum
-
32:12
cancer therapy - chemo, targeted and immunotherapy ❤️
-
4:14
tanoto foundation professorship in medical oncology combats cancer among asian populations
-
15:14
debate: ngs testing for all patients with gi cancers? - yes
-
19:41
dr aditya murali | optimal management of egfrm nsclc patients
-
7:37
debate: msi high colon cancer - upfront chemotherapy
-
17:17
debate: targeted therapy for ras/braf wt left sided colon cancers - egfr antibodies are mandatory
-
3:24
2020 ttf egfr session qa panel srt with osimertinib (tagrisso) first line, stable disease
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
-
7:12
egfr mutated adenocarcinoma - case based panel discussions
-
9:06
debate: is there an optimal treatment for refractory colorectal cancer? - tas-102 or regorafenib
-
6:02
q & a with egfr-mutant lung cancer experts | 2024 living with egfr-mutant lung cancer patient forum
-
7:24
2020 ttf egfr session qa panel does progression always occur on osimertinib (tagrisso)?
-
4:37
case based panel discussion - egfr mutation treated with tagrisso progression while on treatment, an
-
1:55
dr. sun discusses the debate between radiation and chemotherapy in gej cancers